Skip to main content
SpringerLink
Log in

In vitro response of blasts to IL-3, GM-CSF, and G-CSF is different for individual AML patients: factors that stimulate leukemic clonogenic cells also enhance Ara-C cytotoxicity

  • Original Article
  • Published:
Annals of Hematology Aims and scope Submit manuscript

Summary

In vivo, growth factors are currently investigated for their capacity to trigger leukemic stem cells into cycle and thus overcome kinetic drug resistance. In this study, the susceptibility of leukemic clonogenic cells to individual growth factors was related to cytosine-arabinoside (Ara-C) sensitivity. The effects of interleukin-3 (IL-3), granulocyte-macrophage colonystimulating factor (GM-CSF), granulocyte colony-stimulating factor (G-CSF), and combinations of these recombinant hematopoietic factors were tested on blast cells of nine acute myeloid leukemia (AML) patients. Growth factor responses were assessed in semi-solid clonogenic assay and in a 10-day liquid culture followed by clonogenic assay. Heterogeneity in growth factor response was observed in both test systems, resulting in a variable pattern for individual leukemias. In the majority of cases (six of nine) the response patterns in the semi-solid and liquid cultures were divergent. To test the Ara-C sensitivity, leukemic blasts were exposed in liquid to various concentrations of Ara-C in the absence and presence of preselected growth factors. After 10 days, the number of surviving leukemic colony-forming cells (CFU-L) was assessed. Exposure to Ara-C in the presence of optimal stimulatory factor(s) resulted in a 3- to 1000-fold increase of the Ara-C toxicity in seven patients. The Ara-C concentrations resulting in 50% inhibition of clonogenicity (ID50) were 0.48–123 x 10−8 M Ara-C in the absence of stimulatory growth factors, versus only 0.12–0.40 × 10−8 M Ara-C in the presence of these factors. In two patients, addition of one or more factors neither increased the number of CFU-L in liquid nor enhanced the Ara-C toxicity. Even in the absence of growth factors the ID50 values in these cases were as low as 0.20 and 0.28 × 10−8 M Ara-C and in the same range as the ID50 values observed with maximum growth factor stimulation in the other seven patients. These results indicate that Ara-C cytotoxicity can be enhanced by individually selected, clonogenic cell growth-promoting hematopoietic factors.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton AG, Gralnick HR, Sultan C (1985) Proposed revised criteria for the classification of acute myeloid leukemia: a report of the French-American-British Cooperative Group. Ann Intern Med 103:626–629

    Google Scholar 

  2. Bettelheim P, Valent P, Andreeff M, Tafuri A, Haimi J, Gorischek C, Muhm M, Sillaber C, Haas O, Vieder L, Maure D, Schulz G, Speiser W, Geissler K, Kier P, Hinterberge W, Lechner K (1991) Recombinant human granulocyte-macrophage colony-stimulating factor in combination with standard induction chemotherapy in de novo acute myeloid leukemia. Blood 77:700–711

    Google Scholar 

  3. Brach M, Klein H, Platzer E, Mertelsmann R, Herrmann F (1990) Effect of interleukin 3 on cytosine arabinoside-mediated cytotoxicity of leukemic myeloblasts. Exp Hematol 18:748–753

    Google Scholar 

  4. Brons PPT, Haanen C, Boezeman JBM, Muus P, Holdrinet RSG, Pennings AHM, Wessels HMC, De Witte T (1993) Proliferation patterns in acute myeloid leukemia: leukemic clonogenic growth and in vivo cell cycle kinetics. Ann Hematol 66:225–233

    Google Scholar 

  5. Broxmeyer HE, Cooper S, Williams DE, Hangoc G, Gutterman JU, Vadhan-Raj S (1988) Growth characteristics of marrow hematopoietic progenitor/precursor cells from patients on a phase-I clinical trial with purified recombinant human granulocyte-macrophage colony-stimulating factor. Exp Hematol 16:594–602

    Google Scholar 

  6. Butturini A, Santucci MA, Gale RP, Perocco P, Tura S (1990) GM-CSF incubation prior to treatment with cytarabine or doxorubicin enhances drug activity against AML cells in vitro: a model for leukemia chemotherapy. Leukemia Res 14:743–749

    Google Scholar 

  7. Cannistra SA, Groshek P, Griffin JD (1989) Granulocytemacrophage colony-stimulating factor enhances the cytotoxic effects of cytosine arabinoside in acute myeloblastic leukemia and in the myeloid blast crisis phase of chronic myeloid leukemia. Leukemia 3:328–334

    Google Scholar 

  8. Clark SC, Kamen R (1987) The human hematopoietic colonystimulating factors. Science 236:1229–1237

    Google Scholar 

  9. Clarkson BD, Fried J, Strife A, Sakai Y, Ota K, Ohkita T (1970) Studies of cellular proliferation in human leukemia. III. Behavior of leukemic cells in three adults with acute leukemia given continuous infusions of3H-thymidine for 8 to 10 days. Cancer 25:1237–1260

    Google Scholar 

  10. Delwel R, Salem M, Pellens C, Dorssers L, Wagemaker G, Clark S, Löwenberg B (1988) Growth regulation of human acute myeloid leukemia: effects of five recombinant hematopoietic factors in a serum-free system. Blood 72:1944–1949

    Google Scholar 

  11. De Witte T, Gratwohl A, Van Der Lely N, Bacigalupo A, Stern AC, Speck B, Schattenberg A, Nissen C, Gluckman E, Fibbe WE (1990) Recombinant human granulocyte-macrophage colony-stimulating factor accelerates neutrophil and monocyte recovery after allogeneic T-cell-depleted bone marrow transplantation. Blood 79:1359–1365

    Google Scholar 

  12. Donahue RE, Seehra J, Metzger M, Lefebvre D, Rock B, Carbone S, Nathan DG, Garnick M, Sehgal PK, Laston D, La Vallie E, McCoy J, Schendel PF, Norton C, Turner K, Yang YC, Clark SC (1988) Human IL-3 and GM-CSF act synergistically in stimulating hematopoiesis in primates. Science 241:1820–1823

    Google Scholar 

  13. Gerhartz HH, Marcus R, Delmer A, Zwierzina H, De Witte T, Jacobs A, Visani G, Fiére D, Sonneveld P, Labar B, Hoffbrand AV, Fenaux P, Hayat M, Thyss A, Debucher L, Coiffier B, Sizoo W, Willemze R, Ribeiro M, Suciu S, Solby G, Stern A, Zittoun R (1990) Randomized phase-II study with GM-CSF and low dose Ara-C in patients with “high-risk” myelodysplastic syndromes (MDS) (abstr). Blood 76:274a

    Google Scholar 

  14. Griffin JD, Löwenberg B (1986) Clonogenic cells in acute myeloblastic leukemia. Blood 68:1185–1195

    Google Scholar 

  15. Herrmann F, Lindemann A, Klein H, Lübbert M, Schulz G, Mertelsmann R (1989) Effect of recombinant human granulocyte-macrophage colony-stimulating factor in patients with myelodysplastic syndrome with excess blasts. Leukemia 3:335–338

    Google Scholar 

  16. Herrmann F, Mertelsmann R (1989) Polypeptides controlling hematopoietic cell development and activation. Blut 58:117–128

    Google Scholar 

  17. Hoelzer D, Ganser A, Höffken K, Boggaerts M, Lutz D, De Witte T, Diehl V, Sokal S, Ottmann OG, Schulz G (1989) Combination therapy with recombinant human granulocytemacrophage colony-stimulating factor (rhGM-CSF) and lowdose cytosine-arabinoside in patients with myelodysplastic syndromes (MDS) (abstr). Exp Hematol 17:657

    Google Scholar 

  18. Karp JE, Donehower RC, Enterline JP, Dole GB, Fox MG, Burke PJ (1989) In vivo cell growth and pharmacologic determinants of clinical response in acute myelogenous leukemia. Blood 73:24–30

    Google Scholar 

  19. Kufe DW, Spriggs DR, Griffin JD (1987) Pharmacologic studies of low-dose continuous-infusion cytosine arabinoside. Semin Oncol 14 [Suppl 1]:149–158

    Google Scholar 

  20. Lajtha LG (1981) Which are the leukemic cells? Blood Cells 7:43–62

    Google Scholar 

  21. Linssen P, Drenthe-Schonk A, Wessels H, Haanen C (1981) Determination of 1-β-d arabinofuranosylcytosine and 1-β-d arabinofuranosyluracil in human plasma by high-performance liquid chromatography. J Chromat 223:371–378

    Google Scholar 

  22. Lista P, Brizzi MF, Avanzi G, Veglia F, Resegotti L, Pegoraro L (1988) Induction of proliferation of acute myeloblastic leukemia (AML) cells with hemopoietic growth factors. Leukemia Res 12:441–447

    Google Scholar 

  23. Lista P, Porcu P, Avanzi GC, Pegoraro L (1988) Interleukin 3 enhances the cytotoxic activity of 1-β-d-arabinofuranosylcytosine (ara-C) on acute myeloblastic leukaemia (AML) cells. Br J Haematol 69:121–123

    Google Scholar 

  24. Lista P, Brizzi MF, Rossi M, Resegotti L, Clark SC, Pegoraro L (1990) Different sensitivity of normal and leukaemic progenitor cells to Ara-C and IL-3 combined treatment. Br J Haematol 76:21–26

    Google Scholar 

  25. Mayer P, Valent P, Schmidt G, Liehl E, Bettelheim P (1989) The in vivo effects of recombinant human interleukin-3: demonstration of basophil differentiation factor, histamine-producing activity, and priming of GM-CSF-responsive progenitors in nonhuman primates. Blood 74:613–621

    Google Scholar 

  26. McCulloch EA, Till JE (1981) Blast cells in acute myeloblastic leukemia: a model. Blood Cells 7:63–77

    Google Scholar 

  27. Metcalf D (1986) The molecular biology and functions of the granulocyte-macrophage colony-stimulating factors. Blood 67:257–267

    Google Scholar 

  28. Minden MD, Till JE, McCulloch EA (1978) Proliferative state of blast cell progenitors in acute myeloblastic leukemia (AML). Blood 52:592–599

    Google Scholar 

  29. Miyauchi J, Kelleher CA, Yang YC, Wong GG, Clark SC, Minden M, Minkin S, McCulloch EA (1987) The effects of three recombinant growth factors, IL-3, GM-CSF, and G-CSF, on the blast cells of acute myeloblastic leukemia maintained in short-term suspension culture. Blood 70:657–663

    Google Scholar 

  30. Miyauchi J, Kelleher CA, Wang C, Minkin S, McCulloch EA (1989) Growth factors influence the sensitivity of leukemic stem cells to cytosine arabinoside in culture. Blood 73:1272–1278

    Google Scholar 

  31. Murphy MJ (1990) Blood cell growth factors: their biology and clinical applications. Int J Cell Cloning 8:138–145

    Google Scholar 

  32. Murrey W (1972) Numerical methods for unconstrained optimization. Academic, London

    Google Scholar 

  33. Muus P, Drenthe-Schonk A, Haanen C, Linssen P, Wessels J (1987) In vitro studies on phosphorylation and dephosphorylation of cytosine arabinoside in human leukemic cells. Leukemia Res 11:319–325

    Google Scholar 

  34. Nara N, McCulloch EA (1985) The proliferation in suspension of the progenitors of the blast cells in acute myeloblastic leukemia. Blood 65:1484–1493

    Google Scholar 

  35. Oster W, Mertelsmann R, Herrmann F (1989) Role of colony-stimulating factors in the biology of acute myelogenous leukemia. Int J Cell Cloning 7:13–29

    Google Scholar 

  36. Raymakers R, De Witte T, Linssen P, Wessels J, Haanen C (1986) The relation of exposure time and drug concentration on cloning efficiency after incubation of human bone marrow with cytosine arabinoside. Br J Haematol 62:447–453

    Google Scholar 

  37. Raza A, Maheshwari Y, Preisler HD (1987) Differences in cell cycle characteristics among patients with acute nonlymphocytic leukemia. Blood 69:1647–1653

    Google Scholar 

  38. Sieff CA (1987) Hematopoietic growth factors. J Clin Invest 79:1549–1557

    Google Scholar 

  39. Van de Ouweland F, De Witte T, Geerdink P, Haanen C (1982) Enrichment and cryopreservation of bone marrow progenitor cells for autologous reinfusion. Cryobiol 19:292–298

    Google Scholar 

  40. Van Der Lely N, De Witte T, Muus P, Raymakers R, Preijers F, Haanen C (1991) Prolonged exposure to cytosine arabinoside in the presence of hematopoietic growth factors preferentially kills leukemic versus normal clonogenic cells. Exp Hematol 19:267–272

    Google Scholar 

  41. Vellenga E, Ostapovicz D, O'Rourke B, Griffin JD (1987) Effects of recombinant IL-3, GM-CSF, and G-CSF on proliferation of leukemic clonogenic cells in short-term and long-term cultures. Leukemia 1:584–589

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Hematology, Department of Internal Medicine, University Hospital Nijmegen, Geert Grooteplein 8, NL-6525, GA Nijmegen, The Netherlands

    N. Van Der Lely, T. De Witte, J. Wessels, R. Raymakers, P. Muus & F. Preijers

Authors
  1. N. Van Der Lely
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. T. De Witte
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. J. Wessels
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. R. Raymakers
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. P. Muus
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. F. Preijers
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Van Der Lely, N., De Witte, T., Wessels, J. et al. In vitro response of blasts to IL-3, GM-CSF, and G-CSF is different for individual AML patients: factors that stimulate leukemic clonogenic cells also enhance Ara-C cytotoxicity. Ann Hematol 68, 225–232 (1994). https://doi.org/10.1007/BF01737421

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01737421

Key words

Search

Navigation